1. Pink Sheet
  2. >>Biosimilars & Generics

Gottlieb Tells Brand Firms To Sell Samples For Generics – Or Face The Consequences

 
• By Derrick Gingery

The idea could help quiet growing criticism over system gaming and high drug prices.

Gottlieb
Former FDA Commissioner Scott Gottlieb spoke at PhRMA's Innovation Day via video conference from San Francisco. • Source: Derrick Gingery

Former US Food and Drug Administration commissioner Scott Gottlieb wants the pharma industry to actively help generic entry by facilitating sales of samples for testing – if not because they particularly want to but because doing so is in their long-term interest.

Gottlieb, who has returned to advising brand pharmaceutical companies since departing the FDA, made the recommendation during Pharmaceutical Research and Manufacturers of America's Innovation Day event on 25 July

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.